Stock Ratings / Health Care / NAII / financials

BON (45) MTEX (33) AKAN (54) IMCC (64) ⌘ Pro Terminal →

Natural Alternatives International Inc. (NAII) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

Q: Is NAII stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Natural Alternatives International Inc. (NASDAQ: NAII) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $1.11 (-4.31% 1D, market cap $6.9M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, NAII ranks #855 in composite RQD confidence.

Q: How does NAII compare to BON and MTEX in the Health Care sector?

Within the Health Care sector (Medicinal Chemicals and Botanical Products), NAII carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of 7.2%, and ROIC of -10.8%. By comparison, BON (Bon Natural Life Limited (Class A)) holds a D grade (45/100 RQD, P/E N/A, ROIC —, cap $9.2M) and MTEX (Mannatech Incorporated) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $16.1M). Among the 5-stock peer group, NAII leads on earnings multiple (N/A) while NAII leads on capital efficiency (-10.8% ROIC).

Q: What are the biggest fundamental strengths and SEC risk factors for NAII?

Per NAII's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0000787253), Natural Alternatives International Inc. generated $129.9M in revenue (+14.1% YoY), -$13.6M in net income, and $2.3M in free cash flow against $153.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Q: Where is NAII trading relative to its 50-day, 200-day, and 52-week technical levels?

NAII last traded at $1.11 (-4.31% on volume of 38,016 shares), positioning the stock -31.90% below its 50-day simple moving average ($1.63) and -54.69% below its 200-day simple moving average ($2.45). Across its 52-week range of $1.07 to $4.96, NAII sits at the 1.0% percentile with a 14-day RSI of 25.4 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $1.25).

Q: How profitable is Natural Alternatives International Inc. (NAII)?

In FY 2025 (10-K), NAII converted $129.9M of revenue into a 7.2% gross margin, 0% operating margin, and $2.3M in free cash flow (1.8% FCF margin).

$1.11 -4.31% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.10

Natural Alternatives International Inc. (NAII) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $6.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.10 (-0.97%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 1.8% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-10.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NAII)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (34/100 Composite)

🔍 WHY NAII SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+9/20 pts (26% of score)

SEC XBRL FY 2025 (10-K): 1.8% FCF Margin ($2.3M FCF) & 7.2% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (24% of score)

Altman Z-Score 1.45 (DISTRESS RISK (<1.8)) • Piotroski F-Score 4/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$1.14+0.9% Next Q

Q2 (-2Q)

Grade E$1.15+5.2% Next Q

Q3 (-1Q)

Grade E$1.21-8.3% Next Q

Current

Grade E$1.11-8.7% Hist 90D α

Trajectory: D (42) → E (34)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NAII Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NAII currently carries a cautious 34/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.63) and Max Pain ($1.17) forces dealer call-delta covering toward $5.21.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NAII• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “NAII Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”

YES 34%NO 66%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How NAII Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$2.3M (1.8% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $129.9M

FY24

Rev $113.8M

FY25

Rev $129.9M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$129.9M	7.2%	-6.7%	-$13.6M	$2.3M	-10.8%
FY 2024	$113.8M	6%	-7.5%	-$7.2M	-$4.5M	-9.6%
FY 2023	$129.9M	8%	3.6%	$2.5M	$7.0M	-10.8%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NAII)

✓Walkthrough of NAII's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NAII // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -58.43%▼ DESCENDING CHANNEL

2026-10-30O $1.13H $1.13L $1.07C $1.11VOL 2.7K

RES: $2.08SUP: $0.90SMA50: $1.63SMA200: $2.45

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NAII Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NAII Butterfly Map → + Track NAII →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NAII today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NAII. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NAII today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NAII)

Health Care Rank #855 of 1016 ⚔️ BON vs NAII Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NAII vs. BON, MTEX, AKAN, IMCC)

Industry: Medicinal Chemicals and Botanical Products (24 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Natural Alternatives International Inc. (NAII) ranks #855 by composite RQD confidence (34/100, grade E) and #922 by equity capitalization ($6.9M). Within this direct 5-issuer industry benchmark cohort, NAII leads on earnings valuation at N/A trailing P/E, while NAII leads on capital efficiency and profitability with -10.8% ROIC and 7.2% gross margin. IMCC currently holds the highest overall quantitative score in the immediate peer group at 64/100 (C) compared with NAII at 34/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NAII ACTIVE Natural Alternatives International Inc.	E	34/100	—	7.2%	-10.8%	-4.31%	$6.9M	Benchmark Subject
BON Bon Natural Life Limited (Class A)	D	45/100	—	20.8%	—	-0.01%	$9.2M	/bon-vs-naii →
MTEX Mannatech Incorporated	E	33/100	—	74.9%	-35.0%	-2.23%	$16.1M	/mtex-vs-naii →
AKAN Akanda Corp.	D+	54/100	—	—	—	+2.80%	$2.6M	/akan-vs-naii →
IMCC IM Cannabis Corp.	C	64/100	—	—	—	+3.53%	$1.5M	/imcc-vs-naii →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0000787253

In its most recent audited fiscal period (FY2025, filed 2025-06-30), Natural Alternatives International Inc. (NAII) reported GAAP revenue of $129.9M (+14.1% vs. FY2024 revenue of $113.8M ) , GAAP net income of -$13.6M, operating cash flow of $5.9M, and free cash flow of $2.3M (+151.4% YoY). On the balance sheet, NAII closed FY2025 with $153.3M in total assets against $0 in total debt (Altman Z-Score: 1.45, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-06-30	$129.9M	-$13.6M	$5.9M	$2.3M	$153.3M	—
FY2024 (FY)	2024-06-30	$113.8M	-$7.2M	-$1.5M	-$4.5M	$156.1M	—
FY2023 (FY)	2023-06-30	$0	$2.5M	$7.0M	$7.0M	—	—

3. NAII Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NAII stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Natural Alternatives International Inc. (NASDAQ: NAII) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $1.11 (-4.31% 1D, market cap $6.9M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, NAII ranks #855 in composite RQD confidence.

How does NAII compare to BON and MTEX in the Health Care sector?

Within the Health Care sector (Medicinal Chemicals and Botanical Products), NAII carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of 7.2%, and ROIC of -10.8%. By comparison, BON (Bon Natural Life Limited (Class A)) holds a D grade (45/100 RQD, P/E N/A, ROIC —, cap $9.2M) and MTEX (Mannatech Incorporated) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $16.1M). Among the 5-stock peer group, NAII leads on earnings multiple (N/A) while NAII leads on capital efficiency (-10.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NAII?

Per NAII's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0000787253), Natural Alternatives International Inc. generated $129.9M in revenue (+14.1% YoY), -$13.6M in net income, and $2.3M in free cash flow against $153.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NAII trading relative to its 50-day, 200-day, and 52-week technical levels?

NAII last traded at $1.11 (-4.31% on volume of 38,016 shares), positioning the stock -31.90% below its 50-day simple moving average ($1.63) and -54.69% below its 200-day simple moving average ($2.45). Across its 52-week range of $1.07 to $4.96, NAII sits at the 1.0% percentile with a 14-day RSI of 25.4 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $1.25).

NAII Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Natural Alternatives International Inc. (NAII)?

In FY 2025 (10-K), NAII converted $129.9M of revenue into a 7.2% gross margin, 0% operating margin, and $2.3M in free cash flow (1.8% FCF margin).

Direct Sub-Reports: NAII RQD Cockpit NAII 12M Forecast NAII Earnings & Move NAII Dividends & DRIP NAII Insiders & 13F NAII Whale Options NAII Profit Sankey NAII News & Why